Study identifier:D6402C00001
ClinicalTrials.gov identifier:NCT04595370
EudraCT identifier:2020-003126-23
CTIS identifier:N/A
A Phase 2b, Randomised, Double-Blind, Active Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients with Heart Failure and Chronic Kidney Disease
heart failure
Phase 2
No
AZD9977, Dapagliflozin
All
153
Interventional
21 Years - 130 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD9977 Dose A + dapagliflozin 10 mg Participants will receive once daily oral dose A of AZD9977 and 10 mg dapagliflozin for 12 weeks. | Drug: AZD9977 Participants will receive AZD9977 as per the arms they are randomized. Drug: Dapagliflozin Participants will receive dapagliflozin as per the arms they are randomized. |
Experimental: AZD9977 Dose B + dapagliflozin 10 mg Participants will receive once daily oral dose B of AZD9977 and 10 mg dapagliflozin for 12 weeks. | Drug: AZD9977 Participants will receive AZD9977 as per the arms they are randomized. Drug: Dapagliflozin Participants will receive dapagliflozin as per the arms they are randomized. |
Experimental: AZD9977 Dose C + dapagliflozin 10 mg Participants will receive once daily oral dose C of AZD9977 and 10 mg dapagliflozin for 12 weeks. | Drug: AZD9977 Participants will receive AZD9977 as per the arms they are randomized. Drug: Dapagliflozin Participants will receive dapagliflozin as per the arms they are randomized. |
Experimental: Dapagliflozin 10 mg Participants will receive once daily oral dose of dapagliflozin 10 mg alone for 12 weeks. | Drug: Dapagliflozin Participants will receive dapagliflozin as per the arms they are randomized. |